A detailed history of Wells Fargo & Company transactions in Dare Bioscience, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 771 shares of DARE stock, worth $262. This represents 0.0% of its overall portfolio holdings.

Number of Shares
771
Previous 758 1.72%
Holding current value
$262
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$0.31 - $0.57 $4 - $7
13 Added 1.72%
771 $0
Q4 2023

Feb 09, 2024

BUY
$0.29 - $0.53 $34 - $62
118 Added 18.44%
758 $0
Q3 2023

Nov 13, 2023

BUY
$0.46 - $0.91 $8 - $17
19 Added 3.06%
640 $0
Q2 2023

Aug 15, 2023

BUY
$0.91 - $1.05 $30 - $35
34 Added 5.79%
621 $0
Q1 2023

May 12, 2023

BUY
$0.87 - $1.36 $7 - $12
9 Added 1.56%
587 $0
Q4 2022

Feb 13, 2023

SELL
$0.82 - $1.03 $8,187 - $10,284
-9,985 Reduced 94.53%
578 $0
Q3 2022

Nov 14, 2022

BUY
$1.04 - $1.27 $8,315 - $10,154
7,996 Added 311.49%
10,563 $11,000
Q2 2022

Aug 12, 2022

BUY
$0.94 - $1.76 $89 - $167
95 Added 3.84%
2,567 $3,000
Q1 2022

May 16, 2022

BUY
$1.42 - $2.09 $2,895 - $4,261
2,039 Added 470.9%
2,472 $4,000
Q4 2021

Feb 14, 2022

BUY
$1.42 - $2.13 $186 - $279
131 Added 43.38%
433 $1,000
Q3 2021

Nov 15, 2021

BUY
$1.42 - $2.0 $22 - $32
16 Added 5.59%
302 $1,000
Q2 2021

Aug 16, 2021

BUY
$1.21 - $1.89 $52 - $81
43 Added 17.7%
286 $1,000
Q1 2021

May 13, 2021

BUY
$1.31 - $3.0 $26 - $60
20 Added 8.97%
243 $0
Q4 2020

Feb 09, 2021

BUY
$0.96 - $1.51 $47 - $73
49 Added 28.16%
223 $0
Q3 2020

Nov 05, 2020

BUY
$0.98 - $1.52 $41 - $63
42 Added 31.82%
174 $0
Q2 2020

Aug 13, 2020

BUY
$0.84 - $1.11 $0 - $1
1 Added 0.76%
132 $0
Q1 2020

May 14, 2020

BUY
$0.79 - $1.7 $103 - $222
131 New
131 $0

Others Institutions Holding DARE

About Dare Bioscience, Inc.


  • Ticker DARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,820,896
  • Market Cap $28.8M
  • Description
  • Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription pr...
More about DARE
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.